434 related articles for article (PubMed ID: 15493042)
21. Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia.
Berger U; Engelich G; Reiter A; Hochhaus A; Hehlmann R;
Ann Hematol; 2004 Apr; 83(4):258-64. PubMed ID: 14648019
[No Abstract] [Full Text] [Related]
22. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Johnson JR; Bross P; Cohen M; Rothmann M; Chen G; Zajicek A; Gobburu J; Rahman A; Staten A; Pazdur R
Clin Cancer Res; 2003 Jun; 9(6):1972-9. PubMed ID: 12796358
[TBL] [Abstract][Full Text] [Related]
23. Imatinib: a second look. Longer follow-up in chronic myeloid leukaemia: clear advantages.
Prescrire Int; 2008 Dec; 17(98):226-8. PubMed ID: 19415889
[TBL] [Abstract][Full Text] [Related]
24. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
Ghatnekar O; Hjalte F; Taylor M
Acta Oncol; 2010 Aug; 49(6):851-8. PubMed ID: 20615173
[TBL] [Abstract][Full Text] [Related]
26. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
[TBL] [Abstract][Full Text] [Related]
27. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Branford S; Rudzki Z; Harper A; Grigg A; Taylor K; Durrant S; Arthur C; Browett P; Schwarer AP; Ma D; Seymour JF; Bradstock K; Joske D; Lynch K; Gathmann I; Hughes TP
Leukemia; 2003 Dec; 17(12):2401-9. PubMed ID: 14523461
[TBL] [Abstract][Full Text] [Related]
28. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
Simon W; Segel GB; Lichtman MA
Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
[TBL] [Abstract][Full Text] [Related]
29. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.
Palandri F; Iacobucci I; Castagnetti F; Testoni N; Poerio A; Amabile M; Breccia M; Intermesoli T; Iuliano F; Rege-Cambrin G; Tiribelli M; Miglino M; Pane F; Saglio G; Martinelli G; Rosti G; Baccarani M;
Haematologica; 2008 May; 93(5):770-4. PubMed ID: 18367490
[TBL] [Abstract][Full Text] [Related]
30. [Chronic myelogenous leukemia].
Ohnishi K
Gan To Kagaku Ryoho; 2001 Sep; 28(9):1199-205. PubMed ID: 11579630
[TBL] [Abstract][Full Text] [Related]
31. [Imatinib therapy for patients with chronic myelogenous leukemia].
Usui N
Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812
[TBL] [Abstract][Full Text] [Related]
32. Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
Roche-Lestienne C; Darré S; Laï JL; Facon T; Guilhot J; Preudhomme C
Haematologica; 2005 Jan; 90(1):131-3. PubMed ID: 15642682
[TBL] [Abstract][Full Text] [Related]
33. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
de Lavallade H; Apperley JF; Khorashad JS; Milojkovic D; Reid AG; Bua M; Szydlo R; Olavarria E; Kaeda J; Goldman JM; Marin D
J Clin Oncol; 2008 Jul; 26(20):3358-63. PubMed ID: 18519952
[TBL] [Abstract][Full Text] [Related]
34. [Results of imatinib therapy in late-stage chronic myeloid leukemia after treatment with interferon-alpha].
Molnár L; Nagy A; Dávid M; Szomor A; Méhes G; Kovács G; Losonczy H
Orv Hetil; 2004 Apr; 145(17):901-7. PubMed ID: 15170967
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
Dalziel K; Round A; Stein K; Garside R; Price A
Health Technol Assess; 2004 Jul; 8(28):iii, 1-120. PubMed ID: 15245690
[TBL] [Abstract][Full Text] [Related]
37. Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.
Guilhot F; Gardembas M; Rousselot P; Tulliez M; Vigier M; Buzyn A; Rigal-Huguet F; Legros L; Michallet M; Berthou C; Najman A; Maloisel F; Mahon FX; Facon T; Berthaud P; Guilhot J;
Semin Hematol; 2003 Apr; 40(2 Suppl 2):92-7. PubMed ID: 12783382
[TBL] [Abstract][Full Text] [Related]
38. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
[TBL] [Abstract][Full Text] [Related]
39. [Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ].
Groot MT; Ossenkoppele GJ; Kramer MH; van den Boom G; Huijgens PC; Uyl-de Groot CA
Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1460-5. PubMed ID: 12908349
[TBL] [Abstract][Full Text] [Related]
40. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
Alimena G; Breccia M; Luciano L; Quarantelli F; Diverio D; Izzo B; De Angelis B; Mancini M; Latagliata R; Carmosino I; Nanni M; Picardi M; Rotoli B; Mandelli F; Pane F
Leuk Res; 2008 Feb; 32(2):255-61. PubMed ID: 17692911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]